In 2014, the monoclonal antibody (mab) pembrolizumab (anti-programmed cell death protein 1, anti-PD-1, Merck) has been made available for the treatment of patients with disease progression of ipilimumab-refractory melanoma [2]. The gene discussed is PDCD1; the disease is melanoma.